The Effect of Proton Pump Inhibitor and Polaprezinc Combination Therapy for Healing of Endoscopic Submucosal Dissection-induced Ulcer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02243618|
Recruitment Status : Completed
First Posted : September 18, 2014
Last Update Posted : March 27, 2019
|Condition or disease||Intervention/treatment||Phase|
|Gastric Adenoma Early Gastric Cancer||Drug: Polaprezinc Drug: Rebamipide||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||153 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Actual Study Start Date :||January 14, 2015|
|Actual Primary Completion Date :||April 14, 2016|
|Actual Study Completion Date :||April 14, 2016|
|Active Comparator: Rebamipide group||
Administration of pantoprazole 40 mg q.d. and rebamipide 100 mg t.i.d. for 4 weeks after the ESD.
|Active Comparator: Polaprezinc group||
Administration of pantoprazole 40 mg q.d. and polaprezinc 75 mg b.i.d. for 4 weeks after the ESD.
- Ulcering healing rate [ Time Frame: 4 weeks after the ESD ]Healing rate of the iatrogenic ulcer according to the type of ulcer protective agents (polaprezinc vs. rebamipide).
- Scarring change rate [ Time Frame: 4 weeks after the ESD ]Scarring change rate of the iatrogenic ulcer according to the type of ulcer protective agents (polaprezinc vs. rebamipide).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02243618
|Korea, Republic of|
|Seoul, Korea, Republic of, 120-752|